Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
44 hedge funds and large institutions have $26M invested in Iterum Therapeutics in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 19 closing their positions.
132% more capital invested
Capital invested by funds: $11.2M → $26M (+$14.8M)
0.13% more ownership
Funds ownership: 0.3% → 0.43% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 50 → 44 (-6)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$4.75M |
| 2 |
Millennium Management
New York
|
+$3.59M |
| 3 |
QI
QS Investors
New York
|
+$555K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$168K |
| 5 |
Two Sigma Investments
New York
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$2.17M |
| 2 |
HF
HRT Financial
New York
|
-$563K |
| 3 |
IA
Insight Advisors
Newtown,
Pennsylvania
|
-$388K |
| 4 |
Two Sigma Advisers
New York
|
-$280K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$154K |
ITRM Hedge Fund Activity: Q2 2021 in Review
44 of the 5,639 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q2 2021, worth a combined $26M — up 132% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ITRM and 13 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $4.75M. The largest seller was Frazier Management, exiting entirely with an estimated $2.17M sold.
- 44 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2021, down from 50 in Q1 2021.
- Funds reported $26M of Iterum Therapeutics stock for Q2 2021, up 132% quarter-over-quarter.
- 13 funds opened new Iterum Therapeutics positions in Q2 2021 and 19 closed out, a net change of -6 holders.
- The largest Iterum Therapeutics buyer in Q2 2021 was Renaissance Technologies, an estimated $4.75M added.
- The largest Iterum Therapeutics seller in Q2 2021 was Frazier Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q2 2021.